Negative rheumatoid factor polyarthritis

Summary

Negative rheumatoid factor polyarthritis (MONDO:0043152) is a disease. A subtype of arthritic joint disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	negative rheumatoid factor polyarthritis
Mondo ID	MONDO:0043152
MeSH	C538347
UMLS	C2931825
MedGen	444150
Is cancer (heuristic)	no

Also known as: RF-ve CP · rheumatoid factor negative erosive chronic polyarthritis · rheumatoid factor-negative polyarthritis

Disease family

This is a subtype of arthritic joint disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone inflammation disease › arthritic joint disease › negative rheumatoid factor polyarthritis

Related subtypes (12): chondrocalcinosis, transient arthritis, synovitis, osteoarthritis, periarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, reactive arthritis, adult-onset Still disease, polyarticular arthritis, infective arthritis, hemophilic arthropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.